Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Excision BioTherapeutics to Present at Upcoming Conferences

Excision CEO Daniel Dornbusch Presents at Jefferies Healthcare Conference 2022

Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting

Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Excision BioTherapeutics Expands Management Team with Three Key Appointments

 

Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
 

Temple Researchers Awarded Prestigious Grant from the NIH’s Martin Delaney Collaboratories for HIV Cure Research Program

Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV


 

Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer


 

Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine

Excision BioTherapeutics Appoints Biotech Development and Manufacturing Veteran, Franz Gerner, Ph.D., as CTO & Head of Manufacturing

Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board


 

Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer

 

Excision BioTherapeutics Appoints Biotech Industry R&D Veteran, William Kennedy, M.D., as Senior Vice President, Clinical

Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot


 

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs
 

CRISPR Gene-Editing Shows Promise Against HIV

​

​

​

​

Gene Editing Startups Cut Fine Therapeutic Figures

​

​

​

​

CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer

Excision BioTherapeutics Appoints Veteran Genome Editing Expert

​

​

Excision BioTherapeutics to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit

Biopharma tackles COVID-19, HIV and other viruses with gene and cell therapies

 

Gene-Editing Pipeline Takes Off
--
Clinical trials of genome-editing agents are pushing ex vivo, immuno-oncology and in vivo treatment frontiers.

 

Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination

CRISPR-focused Excision Bio Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.

​

​

​

CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure
 

Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology

​

​

HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development

Enlisting CRISPR in the Quest for an HIV Cure



 

Scientists say they found a cure for HIV in some mice. Humans could be next

 

Excision BioTherapeutics Exclusively Licenses New CRISPR-Cas Gene Editors from UC Berkeley to be Used for Viral Infections

HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures
 

Use of CRISPR Cas9 Gene Editing Therapeutic Shown to Permanently Inactivate HIV-1 in Patient’s Blood for First Time